I am with you on this. A phase 1 trial was already underway when the IPO happened. This saved many years of the initial bio tech wait. Potentially the next trial will be an approval trial for GBM. Means CHM long term isnt a normal bio tech long term.
There is no approved CarT for solid tumor cancers. CHM just posted a 75% stable disease against GBM on the lowest dose in a delivery format that does not represent the true clinical treatment. There is no such thing as a sure thing, but I am buying as many of these sub 30c shares as I can offord.
It wont happen over night. But the results so far tend to suggest patience will be rewarded.
CHM Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)